Skip to NavigationSkip to content


New targeted lung cancer treatment coming to UK under MHRA scheme

The MHRA has issued an Early Access to Medicines Scheme (EAMS) positive scientific opinion for tepotinib, for the treatment of adult patients with advanced Non-Small Cell Lung Cancer (NSCLC).

Tepotinib is a monotherapy developed by Merck, and the positive opinion was issued for patients with NSCLC that are harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.

Sickle cell therapy granted innovation passport by MHRA

Bluebird bio has been granted an innovation passport, under the new UK approval process, for LentiGlobin (bb1111) a promising treatment for the rare blood disorder, sickle cell disease (SCD).

LentiGlobin is an investigational gene therapy treatment currently being investigated in Phase I, II, and III trials.

Biosimilars and Brexit: What’s in store for UK’s biosimilar market?

Published on 02/06/21 at 10:32am

It’s been 15 years since the first biosimilar entered the market, and the impact of these drugs on the healthcare industry has been immense. Now the UK has officially left the EU, what effect will Brexit have on the booming biosimilar market in the UK? Kat Jenkins takes a look at the new regulatory landscape post-Brexit, speaking with British Biosimilar Association’s Technical Director, Paul Fleming

The November 2020 issue of Pharmafocus is available to read free online now!

The latest monthly edition of Pharmafocus is available to read for free online now!

UK life sciences industry does not want no-deal Brexit, says ABPI Chief

Prime Minister Boris Johnson’s sudden change of position that the UK is now expecting a no-deal scenario with the European Union in their ongoing Brexit negotiations has triggered alarm bells in the life sciences industry, with warnings that such an outcome could be disastrous for the supply and cost of medicines as the UK battles a second wave of the COVID-19 pandemic over the winter.

The principle disagreements between the two parties hinge on access to the UK’s fishing waters, but the UK pharmaceutical industry has voiced concern that failure to agree a deal could lead to delays

UK Government tells medicine suppliers to stockpile drugs for no-deal Brexit despite coronavirus concerns

Photo by Rennett Stowe

The British government has contacted medicine suppliers urging them to stockpile drugs for a possible no-deal Brexit, despite the pressure the coronavirus pandemic has had on their current stockpiles.

The government wants to sure up supplies for the general population as well as the National Health Service.

Read the January/February 2020 edition of Pharmafocus online now!

Pharmafocus returns for the New Year with its January/February issue, and things have certainly changed since we left. Brexit got done – or at least, the first step in a long process – and the UK will leave the European Union at 11pm on 31 January.

It’s a path paved with uncertainty, but it does provide clarity for business and industry which have been previously unable to plan ahead in such a divided climate.

Majority of British people worried about the fate of the NHS in post-Brexit US trade deal, survey reveals

In a newly released survey on “Over-The-Counter (OTC) and Pharma 2019”, by the business data platform Statista, 55% of people surveyed were concerned about the potential post-Brexit trade deal with the US and its impact on the NHS.

The survey assessed the responses of more than 2,000 British consumers. The NHS being part of a UK-US trade deal was first touted back in June by US Ambassador to the UK, Woody Johnson.

Damage control: How will pharma manage the health economic impacts of Brexit?

Published on 23/10/19 at 10:00am

When it comes to life sciences and patient outcomes, the UK’s destiny is inextricably tied to its relationship with the EU. With services already stretched to breaking point and key patients already unable to access the crucial medicines they need, how will the UK’s health economics be hit by an incoming Brexit?

“No deal” Brexit and life sciences: What happens?

Published on 21/10/19 at 10:51am

Prime Minister Boris Johnson may have agreed a withdrawal agreement with the European Union at the 11th hour, but despite the best efforts of UK Parliament a "no deal" exit could still present a viable threat. It's still all to play for over the next week or so in Westminster, but in the event that the Prime Minister's deal does not gain the support of Parliament or if "no deal" emerges at a later date, where does this leave the UK’s life sciences? Tim Matthews, Partner at legal firm Barlow Robbins LLP, explains.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches